VivoSeq
Other

Laryngospasm

3

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Laryngospasm is an early-stage landscape with 3 programs across 1 company. The most active players are Milestone Pharmaceuticals Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Terminated1 · 33%
Completed1 · 33%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

The Effect of Intravenous Lidocaine on Post-extubation Laryngospasm
Terminated·KKing Saud University·N/A·NCT01445847·134 enrolled
Levobupivacaine vs Levobupivacaine + Dexmedetomidine Infiltration for Post-tonsillectomy Analgesia and Laryngospasm in Pediatric Patients
Completed·—·Phase 1/2·NCT04113720·90 enrolled
Comparsion of Intravenous Injection of Magnesium Sulfate and Lidocaine Effectiveness on the Prevention of Laryngospasm and Analgesic Requirement in Tonsillectomy
Not yet recruiting·—·Phase 3·NCT06761547·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)